No commercial agreement yet. NICE to discuss Spinraza at another meeting
NICE has not yet been able to recommend Spinraza, and an urgent Committee meeting has been called.
Spinraza EAP opens in Russia
An Expanded Access Programme of Spinraza starts in Russia today.
France decides to offer Spinraza to all
Today the French Ministry of Health authorised wide reimbursement of Spinraza. Now every SMA patient in France will be able to receive life-saving treatment.
NICE silence on Spinraza approval. TreatSMA demands action from NHS England
So I guess our silence is fairly obvious. We have heard nothing from NICE, not a single word.
AveXis discloses data on AVXS-101 efficacy in treating early onset spinal muscular atrophy
Avexis, the company behind gene replacement therapy AVXS-101, disclosed preliminary data from their phase-3 clinical trial of intravenous AVXS-101 (Zolgensma). The effects are simply breathtaking!
Will NICE recommend Spinraza tomorrow?
We are all waiting for NICE's decision on Spinraza which is planned for tomorrow.
A new clinical trial opens in presymptomatic babies
As communicated by Roche, the first site to run the Rainbowfish clinical trial had been activated and is ready to accept presymptomatic babies diagnosed with spinal muscular atrophy.